Biostage receives listing deficiency notice from Nasdaq
Biostage announced that it has received a continued listing deficiency notice from The NASDAQ Stock Market because its share price has not met the $1.00 minimum closing bid price requirement for 30 consecutive business days [Nasdaq Listing Rule 5450. This notice has no immediate effect on the Company's Nasdaq listing or the trading of its common stock. Nasdaq has provided Biostage with a 180-day compliance period, until May 17, 2017, in which to regain compliance with the minimum bid price requirement. If at any time during the compliance period, the closing bid price of Biostage's common stock is at least $1.00 per share for at least ten consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed.